Pavel Bogomolov

Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study

Pavel Bogomolov, A. A. Alexandrov, M. V. Macievich et al. · Journal of Hepatology · 2016 · 390 citations

Pharmacy, Internal Medicine, Pharmacotherapy +11

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto et al. · New England Journal of Medicine · 2023 · 215 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +13

A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease

Manuel Romero‐Gómez, Eric Lawitz, R. Ravi Shankar et al. · Journal of Hepatology · 2023 · 192 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial

Heiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov et al. · The Lancet Infectious Diseases · 2022 · 158 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection

Heiner Wedemeyer, Pavel Bogomolov, Antje Blank et al. · Journal of Hepatology · 2018 · 121 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12